Enmai Biotechnology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Enmai Biotechnology - overview
Established
2021
Location
Guangzhou, Guangdong, China
Primary Industry
Pharmaceuticals
About
Based in Guangzhou, China, and founded in 2021, Guangzhou Enmai Biotechnology Co. , Ltd. , trading as Enmai Biotechnology, is an innovative drug developer that develops innovative clinical diagnostic reagents and antibody drugs based on antibody technology, focusing on the integrated precision diagnosis and treatment of sepsis, viral infections, and autoimmune diseases. In February 2026, Enmai Biotechnology raised a series A funding from Xietong Investment and JC Capital.
The company focuses on the research and development of innovative and precision diagnostic technologies for infectious and chronic inflammatory diseases. Its main products include precision diagnostic kits for sepsis, antibody drugs, and innovative diagnostic and treatment solutions. The company’s revenue is generated by providing drugs for infectious and chronic diseases.
Current Investors
JC Capital, Xietong Investment
Primary Industry
Pharmaceuticals
Sub Industries
Medical Devices & Equipment, Pharmaceuticals
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.